Department of Health and Human Services
Participating Organizations
National Institutes
of Health (NIH), (http://www.nih.gov/)
Components of Participating Organizations
National Institute of Allergy and Infectious
Diseases (NIAID), ( http://www.niaid.nih.gov/)
Title: Medical Countermeasures to Restore Gastrointestinal
Function after Radiation Exposure: Project Bioshield (RC1)
Note: The
Project BioShield Act of 2004, enacted on July 21, 2004, authorizes the Secretary, Department of Health and Human Services (DHHS), through the program
carried out by the National Institute of Allergy and Infectious Diseases
(NIAID), National Institutes of Health (NIH), to expedite peer review and award
of grants, contracts, and cooperative agreements to perform, administer, or
support research and development of countermeasures determined by the Secretary
to be a priority to treat, identify, or prevent harm from any biological,
chemical, radiological, or nuclear agent that may cause a public health
emergency affecting national security, or adverse health consequences that may
arise from using such a countermeasure. Consistent with this authority, the
NIAID is announcing a new grant initiative focused on the development of novel
medical countermeasures to restore gastrointestinal function after radiation exposure.
For this special program applications are to be sent directly to NIAID, not to the Division of Receipt and Referral in CSR (see Section IV 3.B).
Announcement Type
New
Request For Applications (RFA) Number: RFA-AI-07-013
Catalog of Federal Domestic Assistance Number(s)
93.855
Key Dates
Release/Posted Date:
December 29,2006
Letters of Intent
Receipt Date(s): February 13,
2007
Application Receipt
Date(s): April 19, 2007
Peer Review Date(s): May, 2007
Council
Review Date(s): August, 2007
Earliest Anticipated
Start Date(s): September, 2007
Additional
Information To Be Available Date (Url Activation Date): http://www.niaid.nih.gov/ncn/budget/qa/
Expiration Date: April 20, 2007
Due Dates for E.O. 12372
Not Applicable
Additional
Overview Content
Executive Summary
Table of Contents
Part
I Overview Information
Part
II Full Text of Announcement
Section
I. Funding Opportunity Description
1. Research
Objectives
Section
II. Award Information
1. Mechanism(s) of
Support
2. Funds Available
Section
III. Eligibility Information
1. Eligible
Applicants
A.
Eligible Institutions
B.
Eligible Individuals
2.Cost Sharing or
Matching
3. Other - Special
Eligibility Criteria
Section
IV. Application and Submission Information
1. Address to
Request Application Information
2. Content and Form
of Application Submission
3. Submission Dates
and Times
A.
Receipt and Review and Anticipated Start Dates
1.
Letter of Intent
B. Sending an Application to the NIH
C. Application Processing
4. Intergovernmental
Review
5. Funding
Restrictions
6. Other Submission
Requirements
Section
V. Application Review Information
1. Criteria
2. Review and
Selection Process
A.
Additional Review Criteria
B.
Additional Review Considerations
C.
Sharing Research Data
D.
Sharing Research Resources
3. Anticipated
Announcement and Award Dates
Section
VI. Award Administration Information
1. Award Notices
2. Administrative
and National Policy Requirements
3. Reporting
Section
VII. Agency Contact(s)
1.
Scientific/Research Contact(s)
2. Peer Review
Contact(s)
3. Financial/ Grants
Management Contact(s)
Section
VIII. Other Information - Required Federal Citations
Part
II - Full Text of Announcement
Section I. Funding Opportunity Description
1. Research Objectives
The Department of
Health and Human Services (DHHS) has assigned the NIH the responsibility to
identify, characterize, and develop new medical countermeasures against radiological or nuclear attacks. A robust research and
development program in this area will begin to yield new diagnostic tools,
radioprotectors and mitigators and therapeutic agents to facilitate an
effective response against radiological injury. On October 14, 2004, the NIH convened an expert panel to review the NIH
Strategic Plan and Research Agenda for Medical Countermeasures against
Radiological and Nuclear Threats (http://www3.niaid.nih.gov/research/topics/radnuc/default.htm). This strategic plan and
research agenda outlines a flexible, collaborative, and comprehensive NIH
research and product development program focused on medical therapies and
diagnostics to counter radiation injury. On behalf
of the NIH, the NIAID is charged with implementing this research agenda.
In most radiation scenarios, injury to the hematopoietic system and gastrointestinal tract are the main determinants of survival. There are currently some medical countermeasures for the management of hematopoietic injury, and additional approaches are in the pipeline. However, there is an urgent need to develop specific countermeasures against the lethality caused by intestinal exposure to radiation and against the pathophysiological manifestations of radiation-induced gastrointestinal injury. The availability of new products that can restore gastrointestinal function after radiation will change the medical management options and outcomes of exposure for a potentially large number of casualties.
The goal of this funding opportunity is to develop medical products that will rapidly and efficiently prevent, mitigate and treat gastrointestinal injury after radiation exposure. This program will support research on mechanisms of radiation-induced injury as well as development of products that will mitigate and treat radiation damage to gastrointestinal system by preventing enterocyte depletion, mucosal barrier break down, mucositis, bacterial translocation, and adverse tissue regeneration with the ultimate goal of increasing survival. The program will also focus on products and methods that will restore gastrointestinal function in terms of barrier protection from microbes, re-equilibration with commensal bacteria, and/or restoration of nutritional transport, reconstitution of mucosal innate and adaptive immunity. Applicants may propose the development of previously identified candidate products relevant to these goals. Product development under this initiative must directly involve the protection or restoration of gastrointestinal function in the context of radiation damage, and be relevant to radiation damage caused by terrorist acts or accidental exposures. For the purpose of this initiative, products are defined as drugs, biologics or other compounds with protective or therapeutic potential, as well as new procedures that result in protection or restoration of the gastrointestinal system using existing compounds.
It is anticipated that candidates that prove efficacious will be advanced towards Food and Drug Administration (FDA) licensure through follow-on support from industry or other government-funded programs. The NIAID will place a high priority on projects that demonstrate advantages over current treatments (such as ease of use in mass casualty settings, ability to deliver treatment post-exposure, and/or reduced toxicity) and have a feasible product development plan for FDA licensure. Studies in animal models will be required to demonstrate efficacy of the products to minimize damage and restore normal function. Clinical studies using human tissue samples or data from irradiated patients may be included, if the results are likely to be relevant to the treatment of humans exposed to terrorist or accidental radiological or nuclear attack. Clinical trials will not be supported under this initiative.
Areas of research and development that are responsive may include, but are not limited to, the following:
This program will not support the following:
See Section
VIII, Other Information - Required Federal Citations, for policies related to
this announcement.
Section
II. Award Information
1. Mechanism(s) of Support
This funding
opportunity will use the NIH Challenge grant (RC1) award mechanism. The RC1 grant is
used by NIAID to support accelerated product research and development efforts
in targeted areas. As an applicant, you will be solely responsible for planning,
directing, and executing the proposed project.
This funding
opportunity uses the just-in-time budget concepts. It also uses the non-modular
budget format described in the PHS 398 application instructions (see http://grants.nih.gov/grants/funding/phs398/phs398.html).
A detailed categorical budget for the "Initial Budget Period" and the
"Entire Proposed Period of Support" is to be submitted with the
application.
2. Funds Available
NIAID intends to commit up to $4.0 million in FY 2006 to support research and development projects under this
initiative. Applicants may request up to $1 million in total costs for a
project period not to exceed eighteen (18) months.
Although
the financial plans of NIAID provide
support for this program, awards pursuant to this funding opportunity are
contingent upon the availability of funds and the receipt of a sufficient
number of meritorious applications.
Section III. Eligibility Information
1. Eligible Applicants
1.A. Eligible
Institutions
You may submit an
application if your organization has any of the following characteristics:
1.B. Eligible Individuals
Any
individual with the skills, knowledge, and resources necessary to carry out the
proposed research is invited to work with their institution to develop an
application for support. Individuals from underrepresented racial and ethnic
groups as well as individuals with disabilities are always encouraged to apply
for NIH programs.
2. Cost Sharing or Matching
Not applicable. The
most current Grants Policy Statement can be found at: http://grants.nih.gov/grants/policy/nihgps_2003/nihgps_Part2.htm#matching_or_cost_sharing.
3. Other-Special Eligibility Criteria
A Principal Investigator (PI) may
submit only one application. A Principal Investigator
can serve as a collaborator in another application provided there is no
scientific overlap. An institution may submit more than one application.
Section
IV. Application and Submission Information
1. Address to Request Application
Information
The PHS 398
application instructions are available at http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive format. Applicants must use the currently approved version of
the PHS 398. For further assistance contact GrantsInfo, Telephone (301)
710-0267, Email: GrantsInfo@nih.gov.
Telecommunications
for the hearing impaired: TTY 301-451-5936.
2. Content and Form of Application Submission
Applications must be
prepared using the most current PHS 398 research grant application instructions
and forms. Applications must have a D&B Data Universal Numbering System
(DUNS) number as the universal identifier when applying for Federal grants or
cooperative agreements. The D&B number can be obtained by calling (866)
705-5711 or through the web site at http://www.dnb.com/us/. The
D&B number should be entered on line 11 of the face page of the PHS 398
form.
The title and number
of this funding opportunity must be typed on line 2 of the face page of the
application form and the YES box must be checked.
3. Submission Dates and Times
Applications must be
received on or before the receipt date described below (Section
IV.3.A). Submission times N/A.
3.A. Receipt, Review and Anticipated Start Dates
Letters of
Intent Receipt Date(s): February 13, 2007
Application Receipt
Date(s): April 19, 2007
Peer Review Date(s): May, 2007
Council
Review Date(s): August, 2007
Earliest Anticipated
Start Date(s): September, 2007
3.A.1. Letter of
Intent
Prospective applicants are asked to submit a letter of
intent that includes the following information:
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
The letter
of intent is to be sent by the date listed at the beginning of this document.
The letter of intent
should be sent to:
Dr. Priti Mehrotra
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
Room 3138, MSC-7616
6700-B Rockledge Drive
Bethesda, MD 20892 (USPS Express or regular mail)
Bethesda, MD 20817 (for
express/courier service)
Telephone: (301) 496-2550
FAX: (301) 402-2638
Email: pm158b@nih.gov
3.B. Sending an Application to
the NIH
Applications
must be prepared as instructed in 6. Other Submission Requirements below.
Send the signed original application, five (5) paper copies, and one (1) CD
with a faithful PDF file copy to:
Dr. Priti
Mehrotra
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
Room 3138, MSC-7616
6700-B Rockledge Drive
Bethesda, MD 20892 (USPS Express or regular mail)
Bethesda, MD 20817 (for
express/courier service)
Telephone: (301) 496-2550
FAX: (301) 402-2638
Email: pm158b@nih.gov
Personal deliveries of applications are no longer permitted (see http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-040.html).
NOTE: Applications must be sent to the above address and not to the Division of Receipt and Referral, Center for Scientific Review, NIH.
3.C. Application Processing
Applications must be received
on or before the application receipt date(s) described above (Section
IV.3.A.). If an application is received after that date, it will be returned
to the applicant without review. Upon receipt, applications will be evaluated
for completeness and responsiveness by the NIAID. Incomplete and
non-responsive applications will not be reviewed.
4. Intergovernmental Review
This initiative is
not subject to intergovernmental
review.
5. Funding Restrictions
All NIH awards are
subject to the terms and conditions, cost principles, and other considerations described
in the NIH Grants Policy Statement. The Grants Policy Statement can be found at http://grants.nih.gov/grants/policy/policy.htm.
Pre-Award Costs are
allowable. A grantee may, at its own risk and without NIH prior approval, incur
obligations and expenditures to cover costs up to 90 days before the beginning
date of the initial budget period of a new or competing continuation award if
such costs: are necessary to conduct the project, and would be allowable under
the grant, if awarded, without NIH prior approval. If specific expenditures
would otherwise require prior approval, the grantee must obtain NIH approval
before incurring the cost. NIH prior approval is required for any costs to be
incurred more than 90 days before the beginning date of the initial budget
period of a new or competing continuation award.
The incurrence of
pre-award costs in anticipation of a competing or non-competing award imposes
no obligation on NIH either to make the award or to increase the amount of the
approved budget if an award is made for less than the amount anticipated and is
inadequate to cover the pre-award costs incurred. NIH expects the grantee to be
fully aware that pre-award costs result in borrowing against future support and
that such borrowing must not impair the grantee's ability to accomplish the
project objectives in the approved time frame or in any way adversely affect
the conduct of the project. See NIH Grants Policy Statement http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part6.htm.
6. Other Submission Requirements
An application with a research plan of no more than fifteen (15) pages must be submitted by April 19, 2007. The application must include the following sections, in the order listed:
*PHS 398 FACE PAGE Must be completed and signed by the appropriate institutional officials (does not count against the page limit). The Face Page form requires a Dun and Bradstreet (D&B) Data Universal Numbering System (DUNS) number. Organizations that do not have a DUNS number may receive one at no cost by calling the dedicated toll-free DUNS number request line at 1-866-705-5711 or via URL http://www.dunandbradstreet.com/. Additional information on this requirement is provided at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-055.html.
*PHS 398 PAGE 2 DESCRIPTION, KEY PERSONNEL, PERFORMANCE SITES, etc. (does not count against page limit).
*PHS 398 PAGES 4 AND 5 BUDGET PAGES (does not count against page limit).
Within the 15 page limit:
Letters of Support For applications that include the use of a specific candidate for basic or regulated studies, applicants must also include letters of support from any collaborators and consultants participating in the proposed research, and corporate sponsors or individuals providing the candidate for the project (does not count against page limit).
Biographical Sketches Provide biographical sketches, not to exceed one (1) page each, for each individual proposed on the project. Provide evidence that the Principal Investigator is qualified to direct this product development effort (does not count against page limit)
*The PHS 398 Face Page form and the PHS 398 Page 2, and the PHS 398 Pages 4 and 5 Budget Pages, along with instructions for completing these forms, can be found at http://www3.niaid.nih.gov/biodefense/bioshield_forms.html.
Appendix Materials
IMPORTANT NOTE: Appendix materials are not allowed. Applications that contain appendix materials will not be reviewed. Applications must be complete. No materials will be accepted after the application receipt deadline.
The letter application must be single-spaced and single-sided, using type no smaller than 11 pt. font and margins no smaller than 0.5 inches on each side, top and bottom.
Additional Instructions and Information
Intellectual Property
NIAID recognizes that intellectual property rights are likely to play an important role in achieving the goals of this program. To this end, the NIAID reminds the applicant that:
To the extent that the project will involve partners, applicants are encouraged to reach early consensus with their proposed partners regarding intellectual property and other legal matters that may arise during the project. In addition, applicants are expected to exercise their Bayh-Dole rights in a manner that does not conflict with the goals of this award or the intent of the Bayh-Dole Act to promote the utilization, commercialization and availability of U.S. Government-funded inventions for public benefit. Finally, applicants are expected to make new information and materials known to the research community in a timely manner through publications, web announcements, and reports to the NIAID or other mechanisms.
Plan for Sharing Research Data
Not applicable.
Sharing Research
Resources
Not applicable.
Section V. Application Review Information
1. Criteria
Only the review
criteria described below will be considered in the review process.
The following will
be considered in making funding decisions:
2. Review and Selection Process
Applications that
are complete and responsive to the FOA will be evaluated for scientific and
technical merit by an appropriate peer review group convened by NIAID in
accordance with the review criteria stated below.
As part of the
initial merit review, all applications will:
The goals
of NIH supported research are to advance our understanding of biological
systems, to improve the control of disease, and to enhance health. In their
written critiques, reviewers will be asked to comment on each of the following
criteria in order to judge the likelihood that the proposed research will have
a substantial impact on the pursuit of these goals. Each of these criteria will
be addressed and considered in assigning the overall score, weighting them as
appropriate for each application. Note that an application does not need to be
strong in all categories to be judged likely to have major scientific impact
and thus deserve a high priority score. For example, an investigator may
propose to carry out important work that by its nature is not innovative but is
essential to move a field forward.
Significance: Does this study address
an important problem? If the aims of the application are achieved, how will
scientific knowledge or clinical practice be advanced? What will be the effect
of these studies on the concepts, methods, technologies, treatments, services,
or preventative interventions that drive this field?
Approach: Are the conceptual or clinical framework, design, methods, and analyses adequately developed, well integrated, well reasoned, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics
Innovation: Is the project original and innovative? For example: Does the project challenge existing paradigms or clinical practice; address an innovative hypothesis or critical barrier to progress in the field? Does the project develop or employ novel concepts, approaches, methodologies, tools, or technologies for this area?
Investigators: Are the investigators appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers? Does the investigative team bring complementary and integrated expertise to the project (if applicable)?
Environment: Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed studies benefit from unique features of the scientific environment, or subject populations, or employ useful collaborative arrangements? Is there evidence of institutional support?
2.A. Additional Review Criteria:
In addition to the
above criteria, the following items will continue to be considered in the
determination of scientific merit and the priority score:
Applications will be reviewed on the basis of: the scientific rationale and technical feasibility of the proposed project to develop medical countermeasures to restore gastrointestinal function after radiation exposure, as well as the probability of technical success; the experience, expertise, and qualification of the project team; and the scientific environment and research facilities. Appropriateness in terms of the overall proposed project and stage of development, as well as the potential for further product development beyond that proposed in order to produce an FDA licensable radiation medical countermeasure, will also be assessed.
Care and Use of Vertebrate Animals
in Research: If vertebrate animals are to be used in the project,
the five items described under Section F of the PHS Form 398 research grant
application instructions will be assessed.
Biohazards: If materials or procedures
are proposed that are potentially hazardous to research personnel and/or the
environment, determine if the proposed protection is adequate.
2.B. Additional
Review Considerations
Budget: The reasonableness of the
proposed budget and the requested period of support in relation to the proposed
research. The priority score should not be affected by the evaluation of the
budget.
2.C. Sharing
Research Data
Not
applicable.
2.D. Sharing Research Resources
Not applicable.
3. Anticipated Announcement and
Award Dates
Not
applicable.
Section
VI. Award Administration Information
1. Award Notices
After the peer
review of the application is completed, a successful PI will be able to access
his or her Summary Statement (written critique) via the eRA Commons.
Awards will be made on the basis of scientific merit as determined by peer review, availability of funds, as well as programmatic priorities.
If the
application is under consideration for funding, NIH will request
"just-in-time" information from the applicant. For details,
applicants may refer to the NIH Grants Policy Statement Part II: Terms and
Conditions of NIH Grant Awards, Subpart A: General (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_part4.htm).
A formal
notification in the form of a Notice of Award (NoA) will be provided to
the applicant organization. The NoA signed by the grants management officer is
the authorizing document. Once all administrative and programmatic issues have
been resolved, the NoA will be generated via email notification from the
awarding component to the grantee business official (designated in item 12 on
the Application Face Page). If a grantee is not email enabled, a hard copy of
the NoA will be mailed to the business official.
Selection of an
application for award is not an authorization to begin performance. Any costs
incurred before receipt of the NoA are at the recipient's risk. These costs may
be reimbursed only to the extent considered allowable pre-award costs. See Also Section
IV.5. Funding Restrictions.
2. Administrative and
National Policy Requirements
All NIH grant and
cooperative agreement awards include the NIH Grants Policy Statement as part of
the NoA. For these terms of award, see the NIH Grants Policy Statement Part II:
Terms and Conditions of NIH Grant Awards, Subpart A: General (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part4.htm)
and Part II Terms and Conditions of NIH Grant Awards, Subpart B: Terms and
Conditions for Specific Types of Grants, Grantees, and Activities (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_part9.htm).
3. Reporting
Not applicable.
Section VII. Agency Contacts
We
encourage your inquiries concerning this funding opportunity and welcome the
opportunity to answer questions from potential applicants. Inquiries may fall
into three areas: scientific/research, peer review, and financial or grants management
issues:
1. Scientific/Research Contacts:
Narayani Ramakrishnan, Ph.D.
Division of Allergy, Immunology and Transplantation
National
Institute of Allergy and Infectious Diseases
Room 4059,
MSC-6601
6610 Rockledge Drive
Bethesda, MD 20892-6601
Telephone: (301) 451-3101
Fax: (301) 480-6597
Email: nramakrishnan@niaid.nih.gov
2. Peer Review Contacts:
Dr.
Priti Mehrotra
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
Room 3138, MSC-7616
6700-B Rockledge Drive
Bethesda, MD 20892
Telephone: (301) 496-2550
FAX: (301) 402-2638
Email: pm158b@nih.gov
3. Financial or Grants
Management Contacts:
Dawn Mitchum, MPH
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
Room 2241,
MSC-7610
6700-B Rockledge Drive
Bethesda, MD 20892-7610
Tel: 301-451-2667
Fax: 301-493-0597
Email: dmitchum@niaid.nih.gov
Section VIII. Other Information
Required Federal Citations
Use of Animals in
Research:
Recipients of PHS
support for activities involving live, vertebrate animals must comply with PHS
Policy on Humane Care and Use of Laboratory Animals (http://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf)
as mandated by the Health Research Extension Act of 1985 (http://grants.nih.gov/grants/olaw/references/hrea1985.htm),
and the USDA Animal Welfare Regulations (http://www.nal.usda.gov/awic/legislat/usdaleg1.htm)
as applicable.
Access to
Research Data through the Freedom of Information Act:
The Office of
Management and Budget (OMB) Circular A-110 has been revised to provide access
to research data through the Freedom of Information Act (FOIA) under some
circumstances. Data that are (1) first produced in a project that is supported
in whole or in part with Federal funds and (2) cited publicly and officially by
a Federal agency in support of an action that has the force and effect of law
(i.e., a regulation) may be accessed through FOIA. It is important for
applicants to understand the basic scope of this amendment. NIH has provided
guidance at http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.
Applicants may wish to place data collected under this funding opportunity in a
public archive, which can provide protections for the data and manage the
distribution for an indefinite period of time. If so, the application should include
a description of the archiving plan in the study design and include information
about this in the budget justification section of the application. In addition,
applicants should think about how to structure informed consent statements and
other human subjects procedures given the potential for wider use of data
collected under this award.
NIH Public Access
Policy:
NIH-funded
investigators are requested to submit to the NIH manuscript submission (NIHMS)
system (http://www.nihms.nih.gov/) at
PubMed Central (PMC) an electronic version of the author's final manuscript
upon acceptance for publication, resulting from research supported in whole or
in part with direct costs from NIH. The author's final manuscript is defined as
the final version accepted for journal publication, and includes all
modifications from the publishing peer review process.
NIH is requesting
that authors submit manuscripts resulting from 1) currently funded NIH research
projects or 2) previously supported NIH research projects if they are accepted
for publication on or after May 2, 2005. The NIH Public Access Policy applies
to all research grant and career development award mechanisms, cooperative
agreements, contracts, Institutional and Individual Ruth L. Kirschstein
National Research Service Awards, as well as NIH intramural research studies.
The Policy applies to peer-reviewed, original research publications that have
been supported in whole or in part with direct costs from NIH, but it does not
apply to book chapters, editorials, reviews, or conference proceedings.
Publications resulting from non-NIH-supported research projects should not be
submitted.
For more information
about the Policy or the submission process please visit the NIH Public Access
Policy Web site at http://publicaccess.nih.gov/ and
view the Policy or other Resources and Tools including the Authors' Manual (http://publicaccess.nih.gov/publicaccess_Manual.htm).
URLs in NIH Grant
Applications or Appendices:
All applications and
proposals for NIH funding must be self-contained within specified page
limitations. Unless otherwise specified in an NIH solicitation, Internet
addresses (URLs) should not be used to provide information necessary to the
review because reviewers are under no obligation to view the Internet sites.
Furthermore, we caution reviewers that their anonymity may be compromised when
they directly access an Internet site.
Healthy People
2010:
The Public Health
Service (PHS) is committed to achieving the health promotion and disease
prevention objectives of "Healthy People 2010," a PHS-led national
activity for setting priority areas. This PA is related to one or more of the
priority areas. Potential applicants may obtain a copy of "Healthy People
2010" at http://www.health.gov/healthypeople.
Authority and
Regulations:
This
program is described in the Catalog of Federal Domestic Assistance at http://www.cfda.gov/ in the following citation:
No. 93.855, Immunology, Allergy, and Transplantation Research, and is not
subject to the intergovernmental review requirements of Executive Order 12372
or Health Systems Agency review. Awards are made under the authorization of
Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241
and 284) and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92.
All awards are subject to the terms and conditions, cost principles, and other
considerations described in the NIH Grants Policy Statement. The NIH Grants
Policy Statement can be found at http://grants.nih.gov/grants/policy/policy.htm.
The PHS strongly
encourages all grant recipients to provide a smoke-free workplace and
discourage the use of all tobacco products. In addition, Public Law 103-227,
the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in
some cases, any portion of a facility) in which regular or routine education,
library, day care, health care, or early childhood development services are
provided to children. This is consistent with the PHS mission to protect and
advance the physical and mental health of the American people.
Loan Repayment
Programs:
NIH encourages
applications for educational loan repayment from qualified health professionals
who have made a commitment to pursue a research career involving clinical,
pediatric, contraception, infertility, and health disparities related areas.
The LRP is an important component of NIH's efforts to recruit and retain the
next generation of researchers by providing the means for developing a research
career unfettered by the burden of student loan debt. Note that an NIH grant is
not required for eligibility and concurrent career award and LRP applications
are encouraged. The periods of career award and LRP award may overlap providing
the LRP recipient with the required commitment of time and effort, as LRP
awardees must commit at least 50% of their time (at least 20 hours per week
based on a 40 hour week) for two years to the research. For further
information, please see: http://www.lrp.nih.gov/.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
| ||||||
Department of Health and Human Services (HHS) |
||||||
NIH... Turning Discovery Into Health® Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |